Opinions
Chris Damas
CanniMed Therapeutics
CMED-T
BUY ON WEAKNESS
May 12, 2017
$10.020
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising
This has a good advantage in that they have already expanded, and have 7000 kg per year capacity of dried bud, whereas others are planning that. They can go from sales level of about a tenth of that, to a higher level very quickly. Pesticides and contaminants are a big issue, and this company has pharmaceutical grade manufacturing at their Saskatoon facility of 97,000 ft.². They also have a facility in Michigan. They’ve been doing this for a long time. He likes medical more than recreational. He would wait for a lower price.